Loading...
•
Jun 30, 2020
Lyra Q2 2020 Earnings Report
Lyra Therapeutics reported financial results for the second quarter of 2020 and provided a corporate update.
Key Takeaways
Lyra Therapeutics reported a net loss of $4.5 million for the second quarter of 2020. The company's cash and cash equivalents increased to $86.6 million due to proceeds from its IPO.
Pamela Nelson was appointed as Senior Vice President of Regulatory Affairs.
Robert Richard was appointed as Senior Vice President of Research and Development.
Closed Initial Public Offering (IPO) with gross proceeds of approximately $64 million.
Cash and cash equivalents as of June 30, 2020 were $86.6 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...